[
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_Mutation",
        "Disease":"Hepatocellular Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Refametinib,Sorafenib",
        "Description":"Phase 2 study in Asian patients with unresectable hepatocellular carcinoma. 70 patients received refametinib (BAY 86-9766) plus sorafenib as study treatment. A retrospective biomarker analysis was performed in 69 patients for KRAS, NRAS and BRAF mutations (BEAM technology). 4 patients were identified to harbor RAS mutations. 3 of whom still received study treatment at the cutoff date used for the final data analysis. These 3 patients had achieved confirmed PR, with duration responses ranging from 128 to 382 days. The fourth patient with a RAS mutation discontinued study treatment after 41 days on therapy due to PD. An overall of 4 (6 by modified RECIST) patients achieved PR.",
        "rs value":null,
        "pmid":"PubMed:25294897",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Refametinib + Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01915602",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12D",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Refametinib + Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01915602",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Varlitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03499626",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lapatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00107536",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Varlitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03499626",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00003147",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"rAD-p53",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02509169",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"rAD-p53",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02418988",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V550L",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C552F",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V550M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.1648G>C",
        "AA Mutation":"p.V550L",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.1648G>T",
        "AA Mutation":"p.V550L",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.1654T>C",
        "AA Mutation":"p.C552R",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.1648G>A",
        "AA Mutation":"p.V550M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NOTCH1",
        "Genomic Position":"9:139388896-139440314(-) | 9q34.3",
        "CDS Mutation":null,
        "AA Mutation":"NOTCH1_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ginsenoside Rg3 capsule + Pirarubicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02724358",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"JAK2",
        "Genomic Position":"9:4985245-5128183(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"JAK2_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD1480",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01219543",
        "source_db":"COSMIC"
    }
]